As of May 24
| +0.70 / +1.67%|
The 24 analysts offering 12-month price forecasts for GlaxoSmithKline have a median target of 44.79, with a high estimate of 54.22 and a low estimate of 37.80. The median estimate represents a +4.87% increase from the last price of 42.71.
The current consensus among 28 polled investment analysts is to Hold stock in GlaxoSmithKline. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.